- Potential license partner is a leading commercial stage regenerative medicine company – No assurances can be given that a license agreement will be entered into whether on commercially reasonable terms or otherwise. The Company does not intend to make any further announcements with regard to the license unless and until an agreement is entered into. • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal ...

BADSCs with brown adipogenic potential would represent an exciting new modality for the treatment of obesity and related metabolic disorders. To explore this possibility, BioRestorative developed a 3D Porous Extracellular Matrix-Derived Scaffold for effective cell delivery. Data obtained in high-fat fed NOD-SCID mice transplanted with differentiated BADSCs supported by the 3D scaffold showed significant reductions in weight, triglyceride and blood glucose levels compared to saline-only injected controls. No ...

Company Performance - Biorestorative Therapies reported revenues of $0.04 million for the quarter ended March 2024, exceeding the Zacks Consensus Estimate by 16.67% and up from $0.03 million year-over-year [2] - The company posted a quarterly loss of $0.53 per share, compared to the Zacks Consensus Estimate of a loss of $0.51, and a loss of $1.53 per share a year ago [8] - Biorestorative Therapies has surpassed consensus EPS estimates three times over the last four quarters [9] Stock Performance - Biorestorative Therapies shares have declined approximately 32.8% since the beginning of the year, while the S&P 500 has gained 12.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $0.03 million, and for the current fiscal year, it is -$1.96 on revenues of $0.12 million [5] Industry Context - The Medical - Biomedical and Genetics industry, to which Biorestorative Therapies belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook [13] - The performance of Biorestorative Therapies may be influenced by the overall industry outlook, as top-ranked industries tend to outperform lower-ranked ones significantly [13]

For the Three Months Ended March 31, 2023 Series B Convertible Additional Preferred Stock Common Stock Paid-In Accumulated Shares Amount Shares Amount Capital Deficit Total | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------|-----------|------------|-----------|-------|-------|--------------|----------------|---------------| | Return and cancellation of shares in lieu of payroll tax \nwithholding | - | - | (10,058) ...

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings during the conference. About BioRestorative Therapies, Inc. BioRestorative Therapies, ...

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings during the conference. About BioRestorative Therapies, Inc. BioRestorative Therapies, ...

BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Stephen Kilmer - Head of Investor Relations Lance Alstodt - President, Chief Executive Officer and Chairman of the Board Robert Kristal - Chief Financial Officer Francisco Silva - Vice President of Research and Development Conference Call Participants Michael Okunewitch - the Maxim Group Jonathan Aschoff - ROTH MKM Operator Good afternoon, everyone, and welcome to the BioRestorative The ...

MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today provided an update on its business. "We have successfully executed against key strategic priorities since the start of the year," said Lance Alstodt, BioRestorative's Chief Executive Officer. "The most important of those were to advance our lead clinical program, BRTX-100, and expand our core preclinica ...

— New therapeutic candidate developed using Company's patented ThermoStem® platform — — Candidate has potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved and marketed towards weight loss — — DMF submission and commencement of first-in-human studies targeted for before the end of 2024 — — Expanding the use of ThermoStem® may open the door to big pharma partnership opportunities — MELVILLE, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", ...

— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the U.S. Food and Drug Administration ("FDA") has cleared an important amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the Company's lead cell therapy candidate, ...